All stories tagged :

People

Hyaluronic Acid Based Dermal Fillers Market Analysis Report 2025: Influencers Normalize...

admin
People

Integration of AI is likely to Propel Demand for Chemistry 4.0...

admin
People

Westminster Security Launches New Dedicated Security Service for Private Family Offices

admin
People

Disclosure of total number of voting rights and number of shares...

admin
People

Global Dermal Fillers Market Insights, 2024-2029 – AbbVie, Galderma, Merz Pharma,...

admin
People

Fermentation Chemicals Market Size to Reach USD 132.04 Billion by 2032...

admin
People

Intracorp and Douglas Coupland Unveil 21st Century Rock Garden, Coupland’s Latest...

admin
People

Q2 2024 Saw Retail Ecommerce Revenues Rise by 7.2% Amidst Falling...

admin
People

Cosentino Launches Dekton® Pietra Edition, a timeless style collection with Mediterranean...

admin
People

Five Below Brings the Fun to Back-to-School Season on Any Budget

admin
People

Denver Landscaping Lynx Revolutionizes Home Landscaping Services Across Denver’s Front Range...

admin

Featured

Pr Newswire

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a...

admin
Pr Newswire

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate...

admin
Pr Newswire

BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001...

admin
Pr Newswire

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

admin
admin

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a...

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing...